Gain Therapeutics (GANX)
(Delayed Data from NSDQ)
$1.12 USD
-0.08 (-6.67%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $1.12 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth A Momentum D VGM
Price, Consensus and EPS Surprise
GANX 1.12 -0.08(-6.67%)
Will GANX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for GANX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GANX
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why
Adherex Technologies Inc. (FENC) Lags Q1 Earnings Estimates
GANX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Here's Why Gain Therapeutics (GANX) Could be Great Choice for a Bottom Fisher
Down -25.88% in 4 Weeks, Here's Why You Should You Buy the Dip in Gain Therapeutics (GANX)
Other News for GANX
Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Gain Therapeutics Leadership Changes and Executive Compensation
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease